Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms
NCT00277667Phase 3Completed
- Sponsor
- Lindner Center of HOPE
- Start
- Feb 2004
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of quetiapine (extended-release tablet, brand name: Bipresso) in bipolar disorder (BD), sponsored by Lindner Center of HOPE. Started Feb 2004; status: completed.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00277667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277667.